[go: up one dir, main page]

AR042547A1 - Uso de acidos alfa - feniltiocaboxilico y alfa - feniloxicarboxilico con actividad disminuidora de la glucosa en el suero y de los lipidos en el suero - Google Patents

Uso de acidos alfa - feniltiocaboxilico y alfa - feniloxicarboxilico con actividad disminuidora de la glucosa en el suero y de los lipidos en el suero

Info

Publication number
AR042547A1
AR042547A1 ARP030104731A ARP030104731A AR042547A1 AR 042547 A1 AR042547 A1 AR 042547A1 AR P030104731 A ARP030104731 A AR P030104731A AR P030104731 A ARP030104731 A AR P030104731A AR 042547 A1 AR042547 A1 AR 042547A1
Authority
AR
Argentina
Prior art keywords
serum
alpha
nhc
alkyl
phenyltiocaboxyl
Prior art date
Application number
ARP030104731A
Other languages
English (en)
Inventor
Fabio Giannessi
Maria Ornella Tinti
Pompeo Pessotto
Uomo Natalina Dell
Anna Floriana Sciarroni
Emanuela Tassoni
Tiziana Brunetti
Ferdinando Maria Milazzo
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of AR042547A1 publication Critical patent/AR042547A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)

Abstract

Reivindicación 1: Uso de compuestos de fórmula (1), donde: R es -H; arilo o heteroarilo, mono, bicíclico o tricíclico, posiblemente sustituido con uno o más grupos halógeno, nitro, hidroxi, alquilo y alcoxi, posiblemente sustituido con uno o más grupos halógeno; n es 0-3; P es 0-1; X es -OH, -O-alquilo C1-4; R1 y R2, que pueden ser iguales o diferentes, se seleccionan entre: -H; alquilo C1-5, -COX; Q se selecciona entre: NH, O, S, -NHC(O)O-, NHC(O)NH-, -NHC(O)S-, -OC(O)NH-, -NHC(S)O-, -NHC(S)NH-, -C(O)NH-; e Y es O, S; y sus mezclas racémicas, enantiómeros simples, estereoisómeros o isómeros geométricos, tautómeros y sales farmacéuticamente aceptable, para la preparación de un medicamento para la profilaxis y tratamiento de la hiperlipidemia e hiperglucemia. Reivindicación 15: Composición farmacéutica que contiene como su ingrediente activo al menos un compuesto de fórmula (1) en mezclas con uno o más vehículos y/o ingredientes farmacéuticamente aceptables.
ARP030104731A 2002-12-19 2003-12-19 Uso de acidos alfa - feniltiocaboxilico y alfa - feniloxicarboxilico con actividad disminuidora de la glucosa en el suero y de los lipidos en el suero AR042547A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000629A ITRM20020629A1 (it) 2002-12-19 2002-12-19 Uso di acidi alfa-feniltiocarbossilici e alfa-fenilossicarbossilici ad attivita' ipoglicemizzante e/o ipolipidemizzante.

Publications (1)

Publication Number Publication Date
AR042547A1 true AR042547A1 (es) 2005-06-22

Family

ID=32676886

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104731A AR042547A1 (es) 2002-12-19 2003-12-19 Uso de acidos alfa - feniltiocaboxilico y alfa - feniloxicarboxilico con actividad disminuidora de la glucosa en el suero y de los lipidos en el suero

Country Status (20)

Country Link
US (1) US7375124B2 (es)
EP (1) EP1572180B1 (es)
JP (1) JP2006512362A (es)
KR (1) KR20050085222A (es)
CN (1) CN100393309C (es)
AR (1) AR042547A1 (es)
AT (1) ATE423558T1 (es)
AU (1) AU2003288546B8 (es)
BR (1) BR0317359A (es)
CA (1) CA2506627A1 (es)
DE (1) DE60326382D1 (es)
DK (1) DK1572180T3 (es)
ES (1) ES2321708T3 (es)
IT (1) ITRM20020629A1 (es)
MX (1) MXPA05005848A (es)
PL (1) PL378414A1 (es)
PT (1) PT1572180E (es)
SI (1) SI1572180T1 (es)
TW (1) TWI308564B (es)
WO (1) WO2004056355A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838296B1 (en) * 2004-10-20 2012-08-08 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
AU2007345526B2 (en) 2007-02-01 2013-02-28 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
HRP20150477T8 (hr) 2008-06-26 2016-10-21 Resverlogix Corp. Postupci dobivanja derivata kinazolona
CN102203058B (zh) * 2008-09-05 2014-11-12 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的连接有硫的化合物
AU2010204106B2 (en) 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
MX392179B (es) 2009-03-18 2025-03-21 Resverlogix Corp Nuevos agentes anti-inflamatorios.
TR201818390T4 (tr) 2009-04-22 2019-01-21 Resverlogix Corp Yeni̇ anti̇-i̇nflamatuvar ajanlar
ES2745471T3 (es) 2011-11-01 2020-03-02 Resverlogix Corp Formulaciones orales de liberación inmediata para quinazolinonas sustituidas
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
EP2935253B1 (en) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
KR102662814B1 (ko) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법
WO2021169769A1 (zh) * 2020-02-28 2021-09-02 四川科伦博泰生物医药股份有限公司 芳香族化合物及其药物组合物和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) * 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
GB1121722A (en) * 1966-03-31 1968-07-31 Ici Ltd New carboxylic acid derivatives
GB1422679A (en) * 1972-11-16 1976-01-28 Funai Pharmaceutical Ind Ltd Substituted phenoxy-a-methylpropionic acid derivatives and a process for producing the same
FR2285867A1 (fr) * 1974-09-30 1976-04-23 Lafon Labor Derives du diphenylsulfoxyde
ITRM20020014A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del

Also Published As

Publication number Publication date
US7375124B2 (en) 2008-05-20
AU2003288546B8 (en) 2009-06-11
HK1087007A1 (en) 2006-10-06
PL378414A1 (pl) 2006-04-03
ATE423558T1 (de) 2009-03-15
US20060154979A1 (en) 2006-07-13
ES2321708T3 (es) 2009-06-10
CN1728992A (zh) 2006-02-01
DK1572180T3 (da) 2009-06-02
CA2506627A1 (en) 2004-07-08
PT1572180E (pt) 2009-05-04
TWI308564B (en) 2009-04-11
ITRM20020629A1 (it) 2004-06-20
EP1572180A1 (en) 2005-09-14
WO2004056355A1 (en) 2004-07-08
BR0317359A (pt) 2005-11-08
TW200420531A (en) 2004-10-16
SI1572180T1 (sl) 2009-06-30
MXPA05005848A (es) 2005-08-26
AU2003288546B2 (en) 2009-04-30
KR20050085222A (ko) 2005-08-29
AU2003288546A1 (en) 2004-07-14
JP2006512362A (ja) 2006-04-13
DE60326382D1 (de) 2009-04-09
EP1572180B1 (en) 2009-02-25
CN100393309C (zh) 2008-06-11

Similar Documents

Publication Publication Date Title
UY28510A1 (es) Compuestos quimicos
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
UA84878C2 (ru) Производные 2-пиридона как ингибиторы нейтрофилов эластазы, фармацевтическая композиция на их основе, способ их получения
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
AR042547A1 (es) Uso de acidos alfa - feniltiocaboxilico y alfa - feniloxicarboxilico con actividad disminuidora de la glucosa en el suero y de los lipidos en el suero
UY27740A1 (es) Nuevos compuestos
AR034897A1 (es) Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
SE0302324D0 (sv) Novel compounds
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
SE0302323D0 (sv) Novel compounds
AR047070A1 (es) Derivados de difenilazetidona
NO20070570L (no) Forbindelser.
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
AR047466A1 (es) Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles.
PT861250E (pt) Derivados de amidina e de isotioureia como inibidores de oxido nitrico sintase
DE69816004D1 (de) Pyrrolderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
AR016212A1 (es) Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas
AR054888A1 (es) Derivados de quinolina como agentes antibacterianos
UY28368A1 (es) Agentes terapéuticos
EA200400667A2 (ru) Новые соединения бензотиазина и бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат
WO2003069350A3 (en) Small molecule modulators of apoptosis
AR045278A1 (es) Sales de succinato y malonato de trans-4-((1r, 3s)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina y el uso como medicamento
AR029405A1 (es) Oxazolidinonas derivadas de sultamas y sultonas, composiciones farmaceuticas que las comprenden y el uso de las mismas para la manufactura de un medicamento

Legal Events

Date Code Title Description
FA Abandonment or withdrawal